Lynparza and Alcohol/Food Interactions
There are 2 alcohol/food/lifestyle interactions with Lynparza (olaparib).
Caffeine Olaparib
Moderate Drug Interaction
MONITOR: Coadministration with olaparib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 1A2 and/or 2B6. The proposed mechanism, based on in vitro data, is increased clearance due to olaparib-mediated induction of CYP450 1A2 and/or 2B6.
MANAGEMENT: Caution is advised if olaparib is used concomitantly with drugs that are substrates of CYP450 1A2 and/or 2B6. Pharmacologic response and serum levels should be monitored more closely whenever olaparib is added to or withdrawn from therapy with these drugs. Dosage adjustments may be required if an interaction is suspected.
References (4)
- EMA. European Medicines Agency. European Union (2013) EMA - List of medicines under additional monitoring. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852
- (2024) "Product Information. Lynparza (olaparib)." AstraZeneca Pty Ltd
- (2024) "Product Information. Lynparza (olaparib)." AstraZeneca Canada Inc
- (2024) "Product Information. Lynparza (olaparib)." AstraZeneca UK Ltd, 2
Olaparib Food
Major Food Interaction
GENERALLY AVOID: Grapefruit juice may significantly increase the plasma concentrations of olaparib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In a drug interaction study with 57 patients, mean olaparib systemic exposure (AUC) was increased approximately 2.7-fold by the potent CYP450 3A4 inhibitor itraconazole. Simulations using physiologically-based pharmacokinetic (PBPK) models suggest that a moderate inhibitor (fluconazole) may increase the AUC of olaparib by 2.2-fold. The interaction has not been studied with grapefruit juice. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.
MANAGEMENT: Food containing grapefruit, grapefruit juice, Seville orange (a citrus relative of the grapefruit), or Seville orange juice should be avoided during treatment with olaparib. Some authorities also recommend avoiding starfruit (carambola) and pomegranate.
References (4)
- (2023) "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals
- (2024) "Product Information. Lynparza (olaparib)." AstraZeneca Pty Ltd
- (2024) "Product Information. Lynparza (olaparib)." AstraZeneca Canada Inc
- (2024) "Product Information. Lynparza (olaparib)." AstraZeneca UK Ltd, 2
Switch to consumer interaction data
Lynparza drug interactions
There are 631 drug interactions with Lynparza (olaparib).
Lynparza disease interactions
There are 4 disease interactions with Lynparza (olaparib) which include:
More about Lynparza (olaparib)
- Lynparza consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (17)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: PARP inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Anastrozole
Anastrozole systemic is used for breast cancer, breast cancer, metastatic, endometrial cancer ...
Letrozole
Letrozole systemic is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic ...
Tamoxifen
Tamoxifen blocks the actions of estrogen and is used to treat and prevent some types of breast ...
Estradiol
Estradiol is used to treat symptoms of menopause such as hot flashes, and vaginal dryness, burning ...
Methotrexate
Methotrexate is used to treat certain types of cancer of the breast, skin, head and neck, or lung ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.